ASCO 2019: Front-line pembrolizumab is promising alternative to chemotherapy for advanced gastroesophageal junction and gastric cancers
The KEYNOTE-062 phase III randomised clinical trial achieved its primary endpoint, showing that for patients…
The KEYNOTE-062 phase III randomised clinical trial achieved its primary endpoint, showing that for patients…
The international, randomised phase III MONALEESA-7 trial found that adding ribociclib to standard-of-care endocrine therapy…
Five-year data from the phase Ib KEYNOTE-001 clinical trial show that pembrolizumab was safe and…
Crizotinib was the first drug licensed to treat ALK-positive non-small cell lung cancer (ALK NSCLC).…